John Marenco, MD
Clinical Cardiac Electrophysiology · Springfield, MANPI 1669441374
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 66.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $7,780 and has fallen 79.5% since, to $1,592 in 2025.
Across 312 payments — averaging $85.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$18K
- Medtronic$3K
- Biotronik Inc.$2K
- Boston Scientific$820
- Novartis$523
- Pfizer$439
- plus $2K from 19 others
What the payments were for
- Consulting fees$9,11334%
- Travel & lodging$4,61717%
- Food & beverage$13,06649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 102 | $17,806 |
| Medtronic(2 entities) | 38 | $2,662 |
| Biotronik Inc. | 19 | $2,373 |
| Boston Scientific | 13 | $820 |
| Novartis | 25 | $523 |
| Pfizer | 25 | $439 |
| Biosense Webster, Inc. | 3 | $383 |
| AstraZeneca(2 entities) | 14 | $246 |
| Johnson & Johnson | 13 | $238 |
| Cardiva Medical, Inc. | 10 | $227 |
| Boehringer Ingelheim | 11 | $208 |
| Impulse Dynamics (USA) Inc. | 3 | $195 |
| Alnylam Pharmaceuticals Inc. | 6 | $136 |
| Merck | 6 | $105 |
| Amgen | 5 | $72 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Heartflow, Inc. | 2 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Bridgebio Pharma, Inc. | 1 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Bayer | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$3,306
- AVEIR$3,192
- Quadra Assura CRT Defibrillator$3,038
- Accent Pacemaker$3,038
- ENSITE PRECISION$1,043
- Micra$668
- Assurity Pacemaker$537
- Carto 3$383
- AZURE XT DR MRI SURESCAN$322
- PulseSelect$281
- OPTIMIZER$278
- ENSITE$265
- LINQ II$196
- TactiCath Quartz CFA Catheter$162
- SelectSecure$153
- ViewMate Intracardiac Echo$148
- ViewFlex Xtra ICE Catheter$148
- Farapulse$147
- Zero Gravity$147
- VantageView System$144
How this compares
$26,796 in reported general payments places this provider in the 65th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.
See all clinical cardiac electrophysiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 306 | $390,125 |
| EntrestoSacubitril/Valsartan | 73 | $98,501 |
| XareltoRivaroxaban | 75 | $92,977 |
| MultaqDronedarone Hcl | 74 | $91,938 |
| FarxigaDapagliflozin Propanediol | 20 | $20,964 |
| Metoprolol Succinate | 202 | $4,357 |
| Flecainide Acetate | 71 | $3,699 |
| Rosuvastatin Calcium | 64 | $3,336 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 20 | $2,733 |
| Nadolol | 13 | $2,384 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 68 | $2,349 |
| Atorvastatin Calcium | 97 | $1,686 |
| Dilt-XrDiltiazem Hcl | 37 | $1,435 |
| Propafenone Hcl | 12 | $1,136 |
| Carvedilol | 96 | $1,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $439 | $390,125306 claims |
| NovartisEntresto | $523 | $98,50173 claims |
| Johnson & JohnsonXarelto | $238 | $92,97775 claims |
| Sanofi-aventis U.S. LLCMultaq | $53 | $91,93874 claims |
| AstraZenecaFarxiga | $246 | $20,96420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.
Other clinical cardiac electrophysiology in Springfield
- Nadavaluru ReddySpringfield$69K
- Paul MadajSpringfield$61K
- Fadi ChalhoubSpringfield$29K
- Abhishek BhagatSpringfield$15K
- Elad AnterBoston$3.9M
- Nitesh SoodFall River$668K
- Jagmeet SinghBoston$619K
- Andre DavilaBoston$379K
- Kevin FloydWorcester$278K
- Daniel KramerBoston$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.